Plain-English translation of NCT03809351 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This research study uses a special type of brain imaging called PET/MRI along with a tracer called AV-1451 to detect and measure abnormal tau protein in the brains of people with Alzheimer's disease or at risk for it. Researchers want to understand how tau spreads in different parts of the brain and how it relates to memory problems. The imaging will help doctors learn more about how this disease develops.
Tau protein buildup is a hallmark of Alzheimer's disease, but scientists still don't fully understand how it develops and spreads in different people, especially across different racial and ethnic groups. This study aims to create better pictures of tau in the brain and connect what they see on imaging to a person's cognitive abilities and health risk factors.
You likely qualify if…
You likely don't qualify if…
You will come to the imaging center for one PET/MRI scan. A small amount of radioactive tracer (AV-1451) will be injected into your arm, and then you'll wait about 75–105 minutes before the scan begins. The actual imaging takes place in a combined PET/MRI machine that simultaneously takes pictures of your brain. Your results will be compared with information from your other study visits and tests to help researchers understand the link between tau levels, brain changes, and thinking problems.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States